Navigation Links
NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
Date:5/27/2010

characteristically aggressive with non-specific initial symptoms, making it difficult to diagnose early. Conventional therapies have little impact on prognosis and disease outcome.

Surgical resection of the tumor is currently the only chance for a cure. Without resection, overall median survival is four to six months with an estimated five-year survival rate of 0.4 percent to 5 percent. Resection increases median survival to 13 to 15 months with five-year survival of about 10 percent, which may be extended to 20 months and 24 to 30 percent, respectively, with adjuvant chemotherapy. Unfortunately, only 10 to 15 percent of patients are deemed candidates for resection given the stage of their disease by the time they are diagnosed.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company applying innovative technologies to create new therapeutic agents for patients with cancer and infectious diseases. Its products are designed to enhance the patient's immune system, enabling the body's immune cells to target pathogens and diseased tissues. For more information please visit us at www.newlinkgenetics.com.


'/>"/>
SOURCE NewLink Genetics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NewLink Genetics Corporation Closes $7.5 Million Financing
2. NewLink Genetics to Present Phase 2 Data on HyperAcute(R)-Pancreas Immunotherapy at the American Society of Clinical Oncology Annual Meeting
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
5. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
6. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
7. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
8. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
9. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... for the First Three Months of 2008., COPENHAGEN, May ... three month period ended March 31, 2008.,During this period, Genmab ... million (approx. USD 36 million) for the,first quarter of 2008. ... 80 million (approx. USD 17 million)., An operating loss ...
... SoluLinK, Inc., a leader in,next-generation conjugation products ... of a new product, NanoLink(TM) Streptavidin Magnetic,Microspheres. ... of any commercially available polymer-encapsulated streptavidin,magnetic microsphere. ... throughput robotic applications where high biotin loads,must ...
... 28 The automation of,transaction-based processing is ... the United States. Foresight Corporation of Dublin, ... scale of installations of Transaction,Insight(R) - the ... Transaction automation techniques enable healthcare organizations to,cut ...
Cached Biology Technology:Genmab Announces 2008 First Quarter Results 2Genmab Announces 2008 First Quarter Results 3Genmab Announces 2008 First Quarter Results 4SoluLinK Introduces NanoLink(TM) Streptavidin Magnetic Microspheres 2New Trend Sweeping Nation's Health Plans: Transaction Automation 2
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced ... America Perimeter Security Systems Market" report to their ... The North American perimeter security market is estimated ... to 2019. Although the U.S. market holds a larger ... is expected to grow at a higher CAGR of ...
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... antibacterial chemical found in toothpaste and other products - ... in children. This comes from the Norwegian Environment and ... Public Health is involved. Similar results are reported in ... for decades, but was recently associated with allergies in ...
... in the region,s most important osteoporosis meeting of the ... Lumpur and enjoy a high quality programme that showcases ... you in your clinical practice. View complete programme ... European CME credits / 20 CPD points from the ...
... have some new motivations to serve their kids vegetables. ... and published in Public Health Nutrition , found that ... of both the main entre and the cook. By ... would taste better and thought the server was more thoughtful ...
Cached Biology News:Triclosan in cosmetics and personal care products can increase allergy risk 2New study reveals more inspiring reasons to serve veggies at dinner 2
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
TUNEL Apoptosis Detection Kit...
Biology Products: